Selective Integrin Ligands Promote Cell Internalization of the Antineoplastic Agent Fluorouracil

Area of Science:

• Bioconjugate Chemistry
• Molecular Targeting
• Anticancer Drug Delivery

Background:

• Unselective anticancer agents cause severe side effects.
• Targeted drug conjugates offer a potential solution for selective cancer therapy.
• Integrin ligands can be utilized for targeted delivery of therapeutic payloads.

Purpose of the Study:

• To investigate integrin ligands as targeting moieties for selective delivery of 5-fluorouracil (5-FU).
• To synthesize and evaluate β-lactam-based integrin ligands and their conjugates with 5-FU.
• To assess the selective uptake and efficacy in cancer versus noncancer cells.

Main Methods:

• Synthesis of two fluorescent β-lactam-based integrin ligands.
• Testing of ligand internalization via α4β1 and α5β1 integrins in Jurkat and K562 cancer cells.
• Creation of three 5-FU conjugates with β-lactam-based ligands and linkers.
• Evaluation of compound E's efficacy as an α5β1 integrin agonist for targeted 5-FU delivery.

Main Results:

• Fluorescent ligands showed selective internalization in cancer cells (Jurkat, K562) but not in HEK293 noncancerous cells.
• Three conjugates of ligands and 5-FU were successfully synthesized.
• Compound E, an α5β1 integrin agonist, demonstrated selective 5-FU delivery into tumor cells.
• Selective delivery by compound E resulted in cancer cell death.

Conclusions:

• β-lactam-based integrin ligands can mediate selective cellular uptake in cancer cells.
• Targeted conjugates can effectively deliver cytotoxic drugs like 5-FU to cancer cells.
• Compound E shows promise for selective anticancer therapy, reducing off-target effects.